Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone...

Area of Science:

• Hematology
• Transplantation Medicine
• Medical Genetics

Background:

• Hereditary sideroblastic anemia (HSA) can lead to persistent iron overload, even after successful bone marrow transplantation (BMT).
• Pyridoxine treatment is often ineffective for managing iron overload in some HSA patients.
• Tissue iron overload poses a significant risk for long-term complications.

Purpose of the Study:

• To evaluate the efficacy of a combined phlebotomy and chelation therapy in reducing iron burden in an HSA patient post-BMT.
• To assess the long-term impact of this combined treatment on iron levels and quality of life.

Main Methods:

• Retrospective analysis of a single male HSA patient who underwent allogeneic BMT.
• Implementation of a regular phlebotomy program combined with iron chelation therapy using deferoxamine (DFO) and deferiprone (L1).
• Monitoring of iron parameters including serum ferritin, non-transferrin-bound iron (NTBI), and liver iron concentration over a 10-year follow-up period.

Main Results:

• The combined phlebotomy and chelation therapy led to a significant reduction in the patient's iron burden.
• Over 10 years, serum ferritin, NTBI, and liver iron levels markedly decreased.
• The patient achieved and maintained normal hemoglobin levels and a good quality of life.

Conclusions:

• Combined phlebotomy and chelation therapy is an effective strategy for managing persistent iron overload in hereditary sideroblastic anemia patients following bone marrow transplantation.
• This therapeutic approach can lead to sustained improvement in iron status and overall well-being.